Cargando…

Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)

BACKGROUND: Healthcare decisions are ideally based on clinical trial results, published in study registries, as journal articles or summarized in secondary research articles. In this research project, we investigated the impact of academically and commercially sponsored clinical trials on medical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Blümle, Anette, Wollmann, Katharina, Bischoff, Karin, Kapp, Philipp, Lohner, Szimonetta, Nury, Edris, Nitschke, Kai, Zähringer, Jasmin, Rücker, Gerta, Schumacher, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406615/
https://www.ncbi.nlm.nih.gov/pubmed/34465296
http://dx.doi.org/10.1186/s12874-021-01359-x
_version_ 1783746532728635392
author Blümle, Anette
Wollmann, Katharina
Bischoff, Karin
Kapp, Philipp
Lohner, Szimonetta
Nury, Edris
Nitschke, Kai
Zähringer, Jasmin
Rücker, Gerta
Schumacher, Martin
author_facet Blümle, Anette
Wollmann, Katharina
Bischoff, Karin
Kapp, Philipp
Lohner, Szimonetta
Nury, Edris
Nitschke, Kai
Zähringer, Jasmin
Rücker, Gerta
Schumacher, Martin
author_sort Blümle, Anette
collection PubMed
description BACKGROUND: Healthcare decisions are ideally based on clinical trial results, published in study registries, as journal articles or summarized in secondary research articles. In this research project, we investigated the impact of academically and commercially sponsored clinical trials on medical practice by measuring the proportion of trials published and cited by systematic reviews and clinical guidelines. METHODS: We examined 691 multicenter, randomized controlled trials that started in 2005 or later and were completed by the end of 2016. To determine whether sponsorship/funding and place of conduct influence a trial’s impact, we created four sub-cohorts of investigator initiated trials (IITs) and industry sponsored trials (ISTs): 120 IITs and 171 ISTs with German contribution compared to 200 IITs and 200 ISTs without German contribution. We balanced the groups for study phase and place of conduct. German IITs were funded by the German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF), or by another non-commercial research organization. All other trials were drawn from the German Clinical Trials Register or ClinicalTrials.gov. We investigated, to what extent study characteristics were associated with publication and impact using multivariable logistic regressions. RESULTS: For 80% of the 691 trials, results were published as result articles in a medical journal and/or study registry, 52% were cited by a systematic review, and 26% reached impact in a clinical guideline. Drug trials and larger trials were associated with a higher probability to be published and to have an impact than non-drug trials and smaller trials. Results of IITs were more often published as a journal article while results of ISTs were more often published in study registries. International ISTs less often gained impact by inclusion in systematic reviews or guidelines than IITs. CONCLUSION: An encouraging high proportion of the clinical trials were published, and a considerable proportion gained impact on clinical practice. However, there is still room for improvement. For publishing study results, study registries have become an alternative or complement to journal articles, especially for ISTs. IITs funded by governmental bodies in Germany reached an impact that is comparable to international IITs and ISTs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01359-x.
format Online
Article
Text
id pubmed-8406615
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84066152021-08-31 Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT) Blümle, Anette Wollmann, Katharina Bischoff, Karin Kapp, Philipp Lohner, Szimonetta Nury, Edris Nitschke, Kai Zähringer, Jasmin Rücker, Gerta Schumacher, Martin BMC Med Res Methodol Research Article BACKGROUND: Healthcare decisions are ideally based on clinical trial results, published in study registries, as journal articles or summarized in secondary research articles. In this research project, we investigated the impact of academically and commercially sponsored clinical trials on medical practice by measuring the proportion of trials published and cited by systematic reviews and clinical guidelines. METHODS: We examined 691 multicenter, randomized controlled trials that started in 2005 or later and were completed by the end of 2016. To determine whether sponsorship/funding and place of conduct influence a trial’s impact, we created four sub-cohorts of investigator initiated trials (IITs) and industry sponsored trials (ISTs): 120 IITs and 171 ISTs with German contribution compared to 200 IITs and 200 ISTs without German contribution. We balanced the groups for study phase and place of conduct. German IITs were funded by the German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF), or by another non-commercial research organization. All other trials were drawn from the German Clinical Trials Register or ClinicalTrials.gov. We investigated, to what extent study characteristics were associated with publication and impact using multivariable logistic regressions. RESULTS: For 80% of the 691 trials, results were published as result articles in a medical journal and/or study registry, 52% were cited by a systematic review, and 26% reached impact in a clinical guideline. Drug trials and larger trials were associated with a higher probability to be published and to have an impact than non-drug trials and smaller trials. Results of IITs were more often published as a journal article while results of ISTs were more often published in study registries. International ISTs less often gained impact by inclusion in systematic reviews or guidelines than IITs. CONCLUSION: An encouraging high proportion of the clinical trials were published, and a considerable proportion gained impact on clinical practice. However, there is still room for improvement. For publishing study results, study registries have become an alternative or complement to journal articles, especially for ISTs. IITs funded by governmental bodies in Germany reached an impact that is comparable to international IITs and ISTs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01359-x. BioMed Central 2021-08-31 /pmc/articles/PMC8406615/ /pubmed/34465296 http://dx.doi.org/10.1186/s12874-021-01359-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Blümle, Anette
Wollmann, Katharina
Bischoff, Karin
Kapp, Philipp
Lohner, Szimonetta
Nury, Edris
Nitschke, Kai
Zähringer, Jasmin
Rücker, Gerta
Schumacher, Martin
Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
title Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
title_full Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
title_fullStr Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
title_full_unstemmed Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
title_short Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT)
title_sort investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (impact)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406615/
https://www.ncbi.nlm.nih.gov/pubmed/34465296
http://dx.doi.org/10.1186/s12874-021-01359-x
work_keys_str_mv AT blumleanette investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT wollmannkatharina investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT bischoffkarin investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT kappphilipp investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT lohnerszimonetta investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT nuryedris investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT nitschkekai investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT zahringerjasmin investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT ruckergerta investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact
AT schumachermartin investigatorinitiatedtrialsversusindustrysponsoredtrialstranslationofrandomizedcontrolledtrialsintoclinicalpracticeimpact